EUCTR2018-001036-21-IT进行中（未招募）1 期
Phase II monocentric study on prostate cancer restaging using PET/MR with innovative radiotracers - PCa Restaging- PET/MR
OSPEDALE SAN RAFFAELE0 个研究点目标入组 60 人开始时间: 2018年11月6日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •- Patients with histological diagnosis of prostate cancer.
- •- Patients treated with radical therapy (radical prostatectomy or external beam radiotherapy, with or without adjuvant therapy) showing a serum increase in PSA values = 0.2 ng / mL.
- •- Age = 18 years.
- •- Able to sign the informed consent for the execution of the examination.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 30
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 30
排除标准
- •- Patients <18 years.
- •- Medical conditions that may significantly interfere with study compliance.
- •- Prior or ongoing hormone therapy.
- •- Contraindications to the PET / MR study (eg pacemaker wearers, etc.)
研究者
相似试验
招募中
不适用
Clinical study of prostate cancer dagnositic makers using genetic polymorphismsProstate cancerJPRN-UMIN000019278Kyoto University2,000
未知
不适用
Follow-up study for localized prostate cancer treated by hormonal therapy or radical prostatectomy.Prostate cancerJPRN-UMIN000000570J-CaP study group2,000
已完成
2 期
Single Agent Temsirolimus (Torisel®) in Chemotherapy-naïve Castration-Resistant Prostate Cancer PatientsProstate CancerNCT00919035Oncology Specialists, S.C.21
招募中
不适用
PROstate cancer follow-up care in Secondary and Primary hEalth Care: PROSPEC study.Prostate cancer, survivorship, primary care, secondary care, follow-up, general practitioner, randomised controlled trialDutch: Prostaatcarcinoom, overlevingszorg, eerstelijnszorg, tweedelijnszorg, nazorg, huisarts, gerandomiseerd gecontroleerde trial.NL-OMON24717Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam, The Netherlands390
已完成
2 期
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC PatientsProstate CancerNCT00654186Oncology Specialists, S.C.32